公开(公告)号：US20170253554A1

公开(公告)日：2017-09-07

申请号：US15509214

申请日：2015-09-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter T.W. Cheng ,  Ying Wang ,  Sutjano Jusuf ,  Shiwei Tao ,  Hao Zhang ,  Shung C. Wu ,  Jeffrey A. Robl

IPC: C07C62/34 ,  A61K31/192 ,  C07D307/79 ,  A61K31/343 ,  C07D277/30 ,  A61K31/44 ,  C07D213/55 ,  A61K31/4418 ,  C07D231/12 ,  A61K31/415 ,  C07D213/65 ,  A61K45/06 ,  A61K31/426

CPC classification number: C07C62/34 ,  A61K31/192 ,  A61K31/343 ,  A61K31/415 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4418 ,  C07C59/64 ,  C07C2601/02 ,  C07D207/323 ,  C07D213/55 ,  C07D213/65 ,  C07D231/12 ,  C07D277/30 ,  C07D277/593 ,  C07D307/79 ,  C07D307/82

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein coupled receptor modulators which may be used as medicaments

公开(公告)号：USRE49352E1

公开(公告)日：2023-01-03

申请号：US17011592

申请日：2020-09-03

Applicant: Bristol-Myers Squibb Company

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Badu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: A61K31/4192 ,  A61K31/27 ,  A61K31/454 ,  C07D249/06 ,  C07D401/04 ,  C07D401/14 ,  A61K31/41 ,  C07C62/10

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20220324829A1

公开(公告)日：2022-10-13

申请号：US17224161

申请日：2021-04-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： YAN SHI ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  C07C249/06 ,  C07C403/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11008300B2

公开(公告)日：2021-05-18

申请号：US16744303

申请日：2020-01-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  A61P1/16 ,  A61P19/10 ,  A61P13/12 ,  A61P11/00 ,  C07C249/06 ,  C07C403/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11007180B2

公开(公告)日：2021-05-18

申请号：US16732387

申请日：2020-01-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: C07D401/04 ,  A61K31/4192 ,  C07D401/14 ,  C07D249/06 ,  A61K31/27 ,  A61K31/454 ,  A61K31/41 ,  C07C62/10

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US10071078B2

公开(公告)日：2018-09-11

申请号：US15628104

申请日：2017-06-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: C07D401/04 ,  A61K31/4192 ,  A61K31/27 ,  A61K31/454 ,  C07D401/14 ,  C07D249/06 ,  A61K31/41 ,  C07C62/10

CPC classification number: A61K31/4192 ,  A61K31/27 ,  A61K31/41 ,  A61K31/454 ,  C07C62/10 ,  C07D249/06 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20160039780A1

公开(公告)日：2016-02-11

申请号：US14774276

申请日：2014-03-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Hao Zhang ,  Peter T.W. Cheng ,  Shiwei Tao

IPC: C07D307/79 ,  A61K45/06 ,  C07C255/54 ,  A61K31/192 ,  C07D231/12 ,  A61K31/415 ,  C07C59/72 ,  A61K31/343 ,  A61K31/277

CPC classification number: C07D307/79 ,  A61K31/192 ,  A61K31/277 ,  A61K31/343 ,  A61K31/415 ,  A61K45/06 ,  C07C59/72 ,  C07C255/54 ,  C07C2602/44 ,  C07D231/12

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的GPR120G蛋白偶联受体调节剂。

公开(公告)号：US12195444B2

公开(公告)日：2025-01-14

申请号：US18321092

申请日：2023-05-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/10 ,  A61P35/00 ,  C07C249/06 ,  C07C403/04 ,  C07D249/06 ,  C07D403/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11447475B2

公开(公告)日：2022-09-20

申请号：US16954550

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Yan Shi ,  Robert F. Kaltenbach, III ,  Ying Wang ,  Hao Zhang

IPC: C07D413/04 ,  C07D261/08

Abstract: The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20220249443A1

公开(公告)日：2022-08-11

申请号：US17718760

申请日：2022-04-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: A61K31/4192 ,  C07D401/14 ,  C07D249/06 ,  A61K31/27 ,  A61K31/454 ,  C07D401/04

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.